Benzinga | Sep 1, 2021 08:03AM EDT

Ayala Pharma Highlights Upcoming ePoster Presentations At European Society For Medical Oncology Congress Sept. 16-21, 2021

Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced upcoming ePoster presentations at the European Society for Medical Oncology (ESMO) Virtual Congress 2021, being held September 16-September 21, 2021. Ayala will present preliminary data from the 6mg cohort of the ongoing Phase 2 ACCURACY clinical trial of AL101 for the treatment of recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harbouring Notch-activating mutations in addition to preclinical results from Ayala's new study of AL101 in combination with other drugs for dual targeting of Notch dysregulated tumors.

ePoster details:

Title: ACCURACY: a phase 2 trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring NOTCH-activating mutations (NOTCHmut): results of 6-mg cohort

Presentation Number: 904P

Presenter: Alan L. Ho, M.D., Ph.D., Memorial Sloan Kettering Cancer Center

Title: The gamma secretase inhibitor AL101 combined with other drugs for dual targeting of Notch dysregulated tumor

Presentation Number: 1789P

Presenter: Renata Ferrarotto, M.D., MD Anderson Cancer Center

The two ePosters will be available to registrants of the ESMO Virtual Congress 2021 starting at 8:30 AM CEST (2:30 AM ET) on Thursday, September 16, 2021.